TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK

TD Asset Management Inc lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 23.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 671,780 shares of the biopharmaceutical company’s stock after acquiring an additional 127,488 shares during the period. TD Asset Management Inc owned 0.55% of Cytokinetics worth $36,921,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of CYTK. UMB Bank n.a. increased its position in Cytokinetics by 10.6% during the third quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 169 shares during the last quarter. Fifth Third Bancorp raised its position in shares of Cytokinetics by 32.3% during the 3rd quarter. Fifth Third Bancorp now owns 1,072 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 262 shares during the period. Teacher Retirement System of Texas lifted its holdings in Cytokinetics by 1.1% in the second quarter. Teacher Retirement System of Texas now owns 30,514 shares of the biopharmaceutical company’s stock valued at $1,008,000 after acquiring an additional 341 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in Cytokinetics by 1.6% in the second quarter. Thrivent Financial for Lutherans now owns 28,119 shares of the biopharmaceutical company’s stock valued at $929,000 after acquiring an additional 449 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its position in Cytokinetics by 68.4% in the third quarter. Farther Finance Advisors LLC now owns 1,115 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 453 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a research report on Wednesday, January 21st. The Goldman Sachs Group set a $95.00 price objective on shares of Cytokinetics and gave the company a “buy” rating in a report on Thursday, December 18th. Barclays started coverage on shares of Cytokinetics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $87.00 price target for the company. Bank of America restated a “neutral” rating on shares of Cytokinetics in a report on Wednesday. Finally, Needham & Company LLC increased their price objective on shares of Cytokinetics from $84.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday. Seventeen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $88.83.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Leerink Partners raised its price target from $83 to $84 and kept an “outperform” rating, signaling continued institutional confidence in the stock’s upside potential. Leerink Partners raise
• Positive Sentiment: HC Wainwright continues to rate CYTK a “Buy” with a $136 price target — an aggressive upside relative to current levels, which supports longer-term investor optimism despite near-term volatility. HC Wainwright coverage
• Positive Sentiment: Investor commentary pieces remain bullish (e.g., recent “Why Cytokinetics is a Buy” article), which can help sustain retail interest and buying momentum over time. Why CYTK is a buy
• Neutral Sentiment: Reported short-interest data for late February shows anomalous/zero values (0 shares, 0.0 days-to-cover) — likely a data/reporting issue, so it provides no clear signal about directional pressure.
• Negative Sentiment: Shares moved down after the company’s recent quarterly report missed EPS expectations and triggered a negative market reaction; coverage noted a sharp intraday decline following the results. Weak earnings coverage
• Negative Sentiment: HC Wainwright cut EPS forecasts across FY2026–FY2028 and several quarters (Q1–Q4 2026), materially lowering near‑term profitability expectations even as it held a buy rating — a factor pressuring valuation multiples today. HC Wainwright estimate changes

Cytokinetics Stock Performance

Shares of CYTK stock opened at $62.22 on Friday. Cytokinetics, Incorporated has a fifty-two week low of $29.31 and a fifty-two week high of $70.98. The company has a 50 day moving average price of $64.20 and a 200 day moving average price of $58.58. The stock has a market capitalization of $7.61 billion, a P/E ratio of -9.53 and a beta of 0.54.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The business had revenue of $17.76 million for the quarter, compared to analyst estimates of $8.02 million. During the same period last year, the business posted ($1.26) EPS. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. On average, research analysts forecast that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,200 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total value of $134,728.00. Following the sale, the executive vice president owned 138,552 shares of the company’s stock, valued at $8,484,924.48. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Wendell Wierenga sold 20,000 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $66.14, for a total value of $1,322,800.00. Following the transaction, the director directly owned 32,444 shares of the company’s stock, valued at approximately $2,145,846.16. This represents a 38.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 151,385 shares of company stock worth $9,817,158 in the last quarter. 2.70% of the stock is owned by company insiders.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.